Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Avalon Ventures
AddedFeb 11, 2024
UpdatedJun 28, 2026
Avalon Ventures

Avalon Ventures

Operating

Avalon Ventures: Early-stage venture capital fund specializing in IT and life sciences.

Location
Los Angeles, CA, US
Founded
1983
Firm
Compare
Portfolio
Employees
Website

Investments

Jnana Therapeutics
Jnana Therapeutics

Total Raised

$207M

Rounds

3

Series C$107MNovember 2022
Series B$50MAugust 2021
Series A$50MDecember 2017
Enlaza Therapeutics
Enlaza Therapeutics

Total Raised

$61M

Rounds

1

Seed$61MOctober 2022
Joy
Joy
Series B

Total Raised

$107.1M

Rounds

7

Series A$20MSeptember 2021
Series A$13.3MSeptember 2018
Primer
Primer

Total Raised

$237M

Rounds

8

Series C$110MJune 2021
Janux Therapeutics
Janux Therapeutics
Public

Total Raised

$252.4M

Rounds

5

Series B$125MApril 2021
Series A$56MMarch 2021
Fortis Therapeutics
Fortis Therapeutics

Total Raised

$58M

Rounds

2

Series A$40MMarch 2021
Series A$18MSeptember 2016
Pando
Pando

Total Raised

$11.6M

Rounds

3

Series A$8.5MJune 2020
Seed$3.1MDecember 2017
AristaMD
AristaMD

Total Raised

$53.4M

Rounds

7

Series B$18MMarch 2020
Series A$11MJuly 2016
Simulmedia
Simulmedia

Total Raised

$86.3M

Rounds

7

Series E$29MJune 2019
Memrise
Memrise

Total Raised

$21.8M

Rounds

7

Series B$15.5MJune 2018
BotChain
BotChain

Total Raised

$5M

Rounds

1

Series Unknown$5MMay 2018
Averon
Averon

Total Raised

$20M

Rounds

4

Series A$11.7MMarch 2018
Series A$8.3MOctober 2017
ScoreStream
ScoreStream

Total Raised

$9.5M

Rounds

8

Series A$3.7MNovember 2017
NanoNets
NanoNets
Series A

Total Raised

$11.4M

Rounds

2

Seed$1.4MApril 2017
Piper Networks
Piper Networks

Total Raised

$5.8M

Rounds

1

Series Unknown$5.8MFebruary 2017
Avelas Biosciences
Avelas Biosciences
Public

Total Raised

$41.9M

Rounds

5

Series C$20MAugust 2016
Enlibrium
Enlibrium
Acquired

Total Raised

$15M

Rounds

1

Series A$15MDecember 2015